Korean J Hepatobiliary Pancreat Surg.  1998 Feb;2(1):95-102.

Significance of EGFR and c-erbB-2 Expression in Extrahepatic Bile Duct Cancer

  • 1Department of Surgery, Korea University College of Medicine, Korea.


Until now, surgical treatment of bile duct carcinoma has been unsatisfactory. There have been few reports dealing with the clinical significance of epidermal growth factor receptor(EGFR) and c-erbB-2 in bile duct cancer. To evaluate epidermal growth factor receptor(EGFR) and c-erbB-2 protein as a marker for prognosis, we analyzed the data and outcome of 32 cases of extrahepatic bile duct carcinoma immunohistologically, as well as clinicopathologically. The expressions of EGFR and c-erbB-2 showed in 71.9%(23/32) and 34.4%(11/32), respectively. The expression of EGFR was closely associated with the expression of c-erbB-2 (p<0.05). The expression rate of EGFR was significantly higher in well-differentiated cancer than in poorly-differentiated cancer (p<0.05), but was not related to stage, or lymph node metastasis. The expression of c-erbB-2 was not related to stage, lymph node metastasis, and differentiation. The expressions of EGFR and c-erbB-2 did not correlate with survival. In conclusion, the expression of EGFR or c-erbB-2 may be used as a tumor marker, but not as a prognostic factor in extrahepatic bile duct cancer.


Extrahepatic bile duct cancer; EGFR; c-erbB-2

MeSH Terms

Bile Duct Neoplasms
Bile Ducts
Bile Ducts, Extrahepatic*
Epidermal Growth Factor
Lymph Nodes
Neoplasm Metastasis
Receptor, erbB-2
Epidermal Growth Factor
Receptor, erbB-2
Full Text Links
export Copy
  • Twitter
  • Facebook
Similar articles
Copyright © 2023 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr